57.18
+2.05%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About BioMarin Pharmaceutical
From its filings with the US Securities and Exchange Commission
BioMarin Pharmaceutical is based in Novato, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker BMRN. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $3.22bn and net income of $348.9m. At that date it held total assets of $7.59bn and shareholders' equity of $6.09bn.
BioMarin Pharmaceutical Inc. (BioMarin, we, us or our) is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Our San Rafael, California-based company, founded in 1997, has a proven track record of innovation, with eight commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, we seek to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients.
In 2025, we achieved $3.2 billion in total revenues, including a significant contribution from our ongoing expansion of VOXZOGO, and we continued to grow our commercial business and advance our product candidate pipeline. We believe that the combination of our internal research programs, partnerships and acquisitions of external assets will allow us to continue to develop and commercialize innovative therapies for patients with serious and life-threatening rare diseases and medical conditions. We periodically conduct strategic portfolio assessments of research and development programs to determine which we believe have the strongest combination of scientific merit, opportunity for commercial success and potential value creation for stockholders. Based on such strategic portfolio assessments, certain programs that do not meet our threshold for further development and commercialization could be discontinued.
Quoted from its 10-K, filed 26 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 21 Jul 2009
- Employees
- 3,221
- Website
- bmrn.com ↗
- Head office
- 105 DIGITAL DRIVE, NOVATO, CA, 94949
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Richard MeierNon-Executive Independent Chairman of the Board$719,067
- Mr. Alexander HardyPresident, Chief Executive Officer, Director, since 2023$14.9m
- Mr. Brian MuellerChief Financial Officer, Executive Vice President and Principal Financial Officer$5.5m
- Dr. C. Greg GuyerExecutive Vice President and Chief Technical Officer$5.7m
- Mr. G. Eric DavisExecutive Vice President, Secretary, Chief Legal Officer$5.1m
- Mr. Arpit DaveExecutive Vice President, Chief Digital and Information Officer
- Dr. Gregory FribergExecutive Vice President, Chief Research & Development Officer$7.2m
- Ms. Cristin HubbardExecutive Vice President, Chief Commercial Officer$6.9m
- Ms. Rashmi RamchandaniChief Accounting Officer, Vice President
- Dr. James SabryChief Business Officer
- Ms. Elizabeth AndersonIndependent Director$463,545
- Ms. Barbara BodemIndependent Director$461,170
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 61
- Environment
- 32
- Social
- 99
- Governance
- 51
- Direct emissions (scope 1)
- 14,000 t
- Energy emissions (scope 2)
- 5,000 t
- Women in the workforce
- 50%
- Carbon reduction policy
- No
- Human rights policy
- Yes
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.